Traditional methods of drug manufacturing face significant challenges in meeting the demands of today’s healthcare systems. This global shortage of medicine will necessitate an urgent upgrade to provide both greater accessibility and affordability for patients in need. Innovations in synthetic biology are producing an unprecedented agility to the manufacturing process of essential medicines and offer a remarkable opportunity to reduce our dependence on legacy sources for active pharmaceutical ingredients (APIs) and their key starting materials (KSMs).
Join Christina Smolke, CEO and Co-founder, Antheia, Inc. and Adjunct Professor of Bioengineering of Stanford University as she discusses how biosynthetic technology can expand the number and diversity of drugs that can be made with fermentation technology. Following this discussion, Yi Tang, Parsons Family Professor, Department of Chemical and Biomolecular Engineering, Department of Chemistry and Biochemistry at UCLA will present recent advances in the biosynthesis of natural products in microorganisms with a focus on new approaches in genome mining of natural products like fungi to create novel structures, activities, and completely new compounds.
This ACS Webinar is moderated by Catherine Goodman, Senior Associate Publisher at the American Chemical Society and co-produced with ACS Publications and the ACS Division of Medicinal Chemistry.
What You Will Learn
- What is the role of the IH in anticipation, recognition, evaluation, and control of chemical exposure
- What is the hierarchy of exposure prevention and the fundamentals of engineering controls
- How an IH can work with you to identify and present "take home" chemical exposures to your family